.jpg)
1 hour ago
3
Article content
The CEO’s presentation on the Q1 2026 Results is available at the following link: www.biosyent.com/investors/
Article content
The Company’s Interim Unaudited Condensed Consolidated Financial Statements and Management’s Discussion and Analysis for the three months ended March 31, 2026 and 2025 will be posted on www.sedarplus.ca on May 14, 2026.
Article content
The Company further announces that its Board of Directors has approved a grant of 339 Restricted Share Units (“RSUs”) to a certain employee of the Company pursuant to the Company’s RSU Plan. These RSUs will fully vest within three years on the third anniversary of the applicable grant date.
Article content
For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.
Article content
About BioSyent Inc.
Article content
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Pharmaceutical and Oral Health businesses, both in Canada and internationally.
Article content
Article content
As of the date of this press release, the Company has 11,438,318 common shares outstanding.
Article content
| BioSyent Inc. | ||||||
| Interim Unaudited Condensed Consolidated Statements of Comprehensive Income | ||||||
| In Canadian Dollars | Q1 2026 | Q1 2025 | % Change | |||
| Net Revenues | 13,908,182 | 10,978,960 | 27% | |||
| Cost of Goods Sold | 3,739,946 | 2,641,768 | 42% | |||
| Gross Profit | 10,168,236 | 8,337,192 | 22% | |||
| Operating Expenses and Finance Income/Costs | 6,882,935 | 5,180,821 | 33% | |||
| Net Income Before Tax | 3,285,301 | 3,156,371 | 4% | |||
| Tax (including Deferred Tax) | 940,482 | 836,438 | 12% | |||
| Net Income After Tax | 2,344,819 | 2,319,933 | 1% | |||
| Net Income After Tax % to Net Revenues | 17% | 21% | ||||
| EBITDA1 | 3,639,086 | 3,201,647 | 14% | |||
| EBITDA1% to Net Revenues | 26% | 29% | ||||
Article content
| BioSyent Inc. | ||||||
| Interim Unaudited Condensed Consolidated Statements of Financial Position | ||||||
| AS AT | March 31, 2026 | December 31, 2025 | % Change | |||
| ASSETS | ||||||
| Cash, cash equivalents and short-term investments | $ | 10,900,082 | $ | 28,651,823 | -62 | % |
| Trade and other receivables | 7,487,075 | 4,456,562 | 68 | % | ||
| Inventory | 11,291,008 | 6,416,204 | 76 | % | ||
| Prepaid expenses and deposits | 1,575,746 | 187,977 | 738 | % | ||
| Derivative asset | 5,553 | – | – | |||
| Loans receivable – current | 63,694 | 80,395 | -21 | % | ||
| CURRENT ASSETS | 31,323,158 | 39,792,961 | -21 | % | ||
| Long term investments | 3,293,957 | 3,293,957 | 0 | % | ||
| Loans receivable – current | 61,799 | 61,799 | 0 | % | ||
| Deferred tax asset | 526,742 | 510,932 | 3 | % | ||
| Property and equipment | 1,708,020 | 982,737 | 74 | % | ||
| Intangible assets | 21,828,234 | 4,797,073 | 355 | % | ||
| Goodwill | 3,750,000 | – | – | |||
| TOTAL NON CURRENT ASSETS | 31,168,752 | 9,646,498 | 223 | % | ||
| TOTAL ASSETS | $ | 62,491,910 | $ | 49,439,459 | 26 | % |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||
| CURRENT LIABILITIES | $ | 10,746,839 | $ | 7,215,608 | 49 | % |
| SHORT TERM DEBT | 4,000,000 | – | – | |||
| CONTINGENT CONSIDERATION | 1,816,894 | – | – | |||
| NON CURRENT LIABILITIES | 934,738 | 758,345 | 23 | % | ||
| Total Equity | 44,993,439 | 41,465,506 | 9 | % | ||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 62,491,910 | $ | 49,439,459 | 26 | % |
Article content
Article content
1. EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.
Article content
A reconciliation of EBITDA to NIAT for the three months ended March 31, 2026 and 2025 is provided in the table below:
Article content
| Three Months (Q1) Ended March 31 | ||||
| 2026 | 2025 | |||
| EBITDA | 3,639,086 | 3,201,647 | ||
| Add: Interest Income | 166,792 | 179,010 | ||
| Less: Depreciation – Property, Equipment | (94,112) | (66,907) | ||
| Amortization of Intangible Assets | (394,849) | (144,276) | ||
| Interest Expense | (31,616) | (13,103) | ||
| Income Tax Expense | (940,482) | (836,438) | ||
| NIAT | 2,344,819 | 2,319,933 |
Article content
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: [email protected]
Phone: 905-206-0013
Web: www.biosyent.com
Article content
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Article content
Article content
Article content
Article content
Article content
Article content
English (US)